Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.

被引：0
|
作者：
Phan, Alexandria T.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wolin, Edward M.
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Royal Free Hosp, London NW3 2QG, England
[3] Charite, D-13353 Berlin, Germany
[4] Univ Varmia & Masuria, Olsztyn, Poland
[5] Univ Hosp Vienna, Vienna, Austria
[6] Fac Med 1, Prague, Czech Republic
[7] Gen Teaching Hosp, Prague, Czech Republic
[8] Hop Robert Debre, Reims, France
[9] Univ Kentucky, Lexington, KY USA
[10] VHIO, Barcelona, Spain
[11] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[12] Univ Cattolica Sacro Cuore, Rome, Italy
[13] Ipsen, Les Ulis, France
[14] Hop Beaujon, Clichy La Garenne, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15178
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study.
    Wolin, Edward M.
    Pavel, Marianne
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Lombard-Bohas, Catherine
    Liyanage, Nilani
    Mai, Xuan
    Thanh, Truong
    Ruszniewski, Philippe
    Caplin, Martyn E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies.
    Phan, Alexandria T.
    Wolin, Edward M.
    Fisher, George A.
    Ruszniewski, Philippe B.
    Pavel, Marianne E.
    Liyanage, Nilani
    Strutt, Kristina
    Braun, Stephan
    Caplin, Martyn E.
    Vinik, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [23] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
  • [24] Safety and efficacy of lanreotide autogel/depot (LAN) every 14 days for patients with pancreatic or midgut neuroendocrine tumours (NETs) progressing on LAN every 28 days: The prospective, international CLARINET FORTE study
    Pavel, M.
    Dromain, C.
    Massien, C.
    Houchard, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [27] Safety and Tolerability of Lanreotide Autogel/Depot in Patients With Neuroendocrine Tumors: Pooled Analysis of Clinical Studies
    Phan, Alexandria T.
    Wolin, Edward M.
    Fisher, George A., Jr.
    Ruszniewski, Philippe B.
    Pavel, Marianne E.
    Liyanage, Nilani
    Mirakhur, Beloo
    Braun, Stephan
    Caplin, Martyn E.
    Vinik, Aaron I.
    PANCREAS, 2018, 47 (03) : 351 - 351
  • [28] Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors
    Dromain, Clarisse
    Loaiza-Bonilla, Arturo
    Mirakhur, Beloo
    Beveridge, Thomas J. R.
    Fojo, Antonio Tito
    ONCOLOGIST, 2021, 26 (04): : E632 - E638
  • [29] Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study
    Wolin, Edward M.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Lombard-Bohas, Catherine
    Liyanage, Nilani
    Thanh, Xuan-Mai Truong
    Ruszniewski, Philippe B.
    Caplin, Martyn E.
    Investigators, Clarinet
    PANCREAS, 2018, 47 (03) : 358 - 359
  • [30] Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
    Caplin, Martyn E.
    Pavel, Marianne
    Phan, Alexandria T.
    Cwikla, Jaroslaw B.
    Sedlackova, Eva
    Thanh, Xuan-Mai Truong
    Wolin, Edward M.
    Ruszniewski, Philippe
    ENDOCRINE, 2021, 71 (02) : 502 - 513
12345